GRCE (Grace Therapeutics) E10: $-20.13 (As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics E10?

Grace Therapeutics GRCE -2.71% 31 E10 is $-20.13 as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Grace Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-20.13 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 12.10% per year. During the past 5 years, the average E10 Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Grace Therapeutics was 14.40% per year. The lowest was 6.30% per year. And the median was 12.10% per year.

As of today (2026-06-25), Grace Therapeutics's current stock price is $2.325. Grace Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-20.13. Grace Therapeutics's Shiller PE Ratio of today is .


Grace Therapeutics  (NAS:GRCE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Grace Therapeutics E10 Related Terms


Grace Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics E10 Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.70 -29.68 -22.39 -22.69 -20.13

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.69 -21.72 -21.40 -20.78 -20.13

GRCE vs PSTV, ATNM, NNVC: E10 Comparison

For the Biotechnology subindustry, Grace Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Shiller PE Ratio falls into.


GRCE
31GF Score
Grace Therapeutics Inc GRCE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grace Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.06/330.2130*330.2130
=-0.060

Current CPI (Mar. 2026) = 330.2130.

Grace Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201602 -6.180 237.111 -8.607
201605 -10.673 240.229 -14.671
201608 -8.067 240.849 -11.060
201611 -7.860 241.353 -10.754
201706 -7.012 244.955 -9.453
201709 -11.995 246.819 -16.048
201712 -15.268 246.524 -20.451
201803 -11.364 249.554 -15.037
201806 -8.394 251.989 -11.000
201809 -23.034 252.439 -30.131
201812 -2.467 251.233 -3.243
201903 -8.609 254.202 -11.183
201906 -5.280 256.143 -6.807
201909 -12.000 256.759 -15.433
201912 -6.720 256.974 -8.635
202003 10.080 258.115 12.896
202006 -2.400 257.797 -3.074
202009 -3.120 260.280 -3.958
202012 -1.560 260.474 -1.978
202103 -1.301 264.877 -1.622
202106 -0.720 271.696 -0.875
202109 0.180 274.310 0.217
202112 -0.540 278.802 -0.640
202203 -0.529 287.504 -0.608
202206 -0.610 296.311 -0.680
202209 -0.660 296.808 -0.734
202212 -0.520 296.797 -0.579
202303 -3.910 301.836 -4.278
202306 -0.540 305.109 -0.584
202309 -0.430 307.789 -0.461
202312 -0.210 306.746 -0.226
202403 -0.260 312.332 -0.275
202406 -0.240 314.175 -0.252
202409 -0.300 315.301 -0.314
202412 -0.360 315.605 -0.377
202503 0.100 319.799 0.103
202506 -0.210 322.561 -0.215
202509 -0.060 324.800 -0.061
202512 -0.140 324.054 -0.143
202603 -0.060 330.213 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-20.13 mean?
Grace Therapeutics (GRCE) has a E10 of $-20.13 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' E10 too high?
Grace Therapeutics' current E10 is $-20.13. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' E10 compare to PSTV and ATNM?
Grace Therapeutics' E10 of $-20.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current E10 is $-20.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current E10 of $-20.13. The current E10 is $-20.13. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current E10 is $-20.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price